ArticleScientific reports2015
Identification of an iridium(III) complex with anti-bacterial and anti-cancer activity.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 77 citations in OpenAlex.
- Role of noble and rare earth metals in bioactive materials for medical applications in tissue engineering.RSC advances · 2025Review
- Anticancer efficacy of bis-heteroleptic iridium(iii) complexes with difluoro-substituted phenylpyridine ligands.RSC advances · 2025Article
- Tetrazolium iridium complexes as potential antibacterial agents.RSC advances · 2025Article
- Synthesis and Evaluation of Cytotoxic Activity of RuCp(II) Complexes Bearing (Iso)nicotinic Acid Based Ligands.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Radiosensitization effect of iridium (III) complex on lung cancer cells via mitochondria apoptosis pathway.Frontiers in pharmacology · 2025Article
- Evaluation of multi-target iridium(iii)-based metallodrugs in combating antimicrobial resistance and infections caused byRSC advances · 2024Article
- Review on the Applications of Selected Metal-Based Complexes on Infectious Diseases.Molecules (Basel, Switzerland) · 2024Review
- Antimicrobial Activity of Manganese(I) Tricarbonyl Complexes Bearing 1,2,3-Triazole Ligands.Molecules (Basel, Switzerland) · 2023Article
- New Bis-Cyclometalated Iridium(III) Complexes with β-Substituted Porphyrin-Arylbipyridine as the Ancillary Ligand: Electrochemical and Photophysical Insights.International journal of molecular sciences · 2022Article
- Metal Peptide Conjugates in Cell and Tissue Imaging and Biosensing.Topics in current chemistry (Cham) · 2022Review
- Radical scavenging capacity, antibacterial activity, and quantum chemical aspects of the spectrophotometrically investigated iridium (III) complex with benzopyran derivative.Frontiers in pharmacology · 2022Article
- Evaluation of the Synthesized Novel Iridium (III) Complexes Against HeLa Cell Lines Through In-Silico, In-Vitro and DNA Nicking.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Triazole-based osmium(ii) complexes displaying red/near-IR luminescence: antimicrobial activity and super-resolution imaging.Chemical science · 2020Article
- Use of Cotton Textiles Coated by Ir(III) Tetrazole Complexes within Ceramic Silica Nanophases for Photo-Induced Self-Marker and Antibacterial Application.Nanomaterials (Basel, Switzerland) · 2020Article
- Metal Complexes, an Untapped Source of Antibiotic Potential?Antibiotics (Basel, Switzerland) · 2020Article
- Iridium(III) Complexes Targeting Apoptotic Cell Death in Cancer Cells.Molecules (Basel, Switzerland) · 2019Review
- Synthesis, Characterisation and In Vitro Permeation, Dissolution and Cytotoxic Evaluation of Ruthenium(II)-Liganded Sulpiride and Amino Alcohol.Scientific reports · 2019Article
- Recent Advances on Octahedral Polypyridyl Ruthenium(II) Complexes as Antimicrobial Agents.Polymers · 2018Review
- Cobalt Complex with Thiazole-Based Ligand as NewMolecules (Basel, Switzerland) · 2018Article
- The Discovery of an Iridium(III) Dimer Complex as a Potent Antibacterial Agent against Non-Replicating Mycobacterium smegmatis.Polymers · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Group 9 transition metal complexes have been widely explored as therapeutic agents due to their unique geometry, their propensity to undergo ligand exchanges with biomolecules and their diverse steric and electronic properties. These metal complexes can offer distinct modes of action in living organisms compared to carbon-based molecules. In this study, we investigated the antimicrobial and anti-proliferative abilities of a series of cyclometallated iridium(III) complexes. The iridium(III) complex 1 inhibited the growth of S. aureus with MIC and MBC values of 3.60 and 7.19 μM, respectively, indicating its potent bactericidal activity. Moreover, complex 1 also exhibited cytotoxicity against a number of cancer cell lines, with particular potency against ovarian, cervical and melanoma cells. This cyclometallated iridium(III) complex is the first example of a substitutionally-inert, Group 9 organometallic compound utilized as a direct and selective inhibitor of S. aureus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.